



Dynavax Technologies Corporation
Investor Relations Department
2929 Seventh Street
Berkeley, CA 94710
United States

[Visit IR website](#)

[Sign-up for Email alerts](#)

NASDAQ: DVAX

Last Trade: 9.90

Trade Time: 4:00 PM ET
Jul 25, 2017

Change: -0.75 (-7.042%)

Day Range: 9.70 - 10.80

52-Week Range: 3.20 - 17.50

Volume: 3,407,882

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in m... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jun 2, 2017

[Dynavax Presents Updated Data for SD-101 in Combination with KEYTRUDA\(R\) \(pembrolizumab\) Highlighting an ORR in 7 out of 7 Patients Naive to an Anti-PD-1 or Anti-PD-L1 Therapy](#)

May 19, 2017

[Dynavax to Present Data on SD-101 in Combination with KEYTRUDA\(R\) at the 2017 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#)

May 8, 2017

[Dynavax Reports First Quarter 2017 Financial Results](#)

Apr 3, 2017

[Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B](#)

Mar 20, 2017

[Dynavax Announces Upcoming Data Presentations for Three TLR9 Agonist Programs at the 2017 American Association for Cancer Research Annual Meeting](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 13, 2017

[Annual Report \(10-K\)](#)

Jul 10, 2017

[Proxy Statement \(DEF 14A\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)

Nov 7, 2016

[Quarterly Report \(10-Q\)](#)

Aug 8, 2016

[Quarterly Report \(10-Q\)](#)